Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
16 mars 2023 16h24 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic...
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
14 mars 2023 16h01 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
14 mars 2023 08h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
27 févr. 2023 16h05 HE
|
Adamis Pharmaceuticals Corporation
Combined company will have commercial products and a library of development candidates, two of which are clinical stageWill be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhDLead...
Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
22 févr. 2023 16h01 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
07 nov. 2022 16h05 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Announces Review of Strategic Alternatives
03 oct. 2022 16h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in...
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
12 août 2022 17h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as...
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
10 août 2022 16h02 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
08 août 2022 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...